About me
Marie-Eve Beaulieu, PhD is General Manager of Nostrum Biodiscovery, a Barcelona- and Boston-based computational drug discovery technology company developing physics-based AI platforms for therapeutic design. She brings over 15 years of experience spanning drug discovery and executive leadership in biotech. Prior to Nostrum, she served as CSO of Peptomyc, where she led the development of OMO-103 - the first direct MYC inhibitor to reach clinical trials - from preclinical stage through Phase I/II.
